ArticleCancer research and treatment2023
Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder.
Article in Cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta-analysis.BJU international · 2026Pooled it
- Assessing clinical complete response after neoadjuvant systemic therapy in muscle-invasive bladder cancer: a systematic review.World journal of urology · 2025Pooled it
- Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies.Cancer research and treatment · 2024Trial
- Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice.BJU international · 2026Review
- Advances in the management of localized bladder cancers.Nature reviews. Clinical oncology · 2026Review
- Choosing neoadjuvant therapy for muscle-invasive bladder cancer based on efficacy-safety trade-off: a network meta-analysis.Frontiers in oncology · 2026Review
- Improving Urothelial Carcinoma Outcomes: The Powerful Combination of Neoadjuvant and Adjuvant Chemotherapy in the Perioperative Period.Annals of surgical oncology · 2025Article
- Optimizing enfortumab vedotin plus pembrolizumab therapy.Oncotarget · 2025Review
- Novel neoadjuvant therapies for muscle-invasive bladder cancer: Systematic review and meta-analysis.BJUI compass · 2025Review
- Neoadjuvant immunotherapy for muscle-invasive bladder cancer: a 2025 update.Immunotherapy · 2025Review
- The practical roadmap for peri-cystectomy approaches in muscle-invasive bladder cancer.Frontiers in oncology · 2025Review
- Comparison of neoadjuvant chemotherapy and combined chemotherapy with immunotherapy for muscle-invasive bladder cancer: a propensity score-matched analysis.American journal of translational research · 2025Article
- Oncolytic viruses: a promising therapy for malignant pleural effusion and solid tumors.Frontiers in immunology · 2025Review
- Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing.Frontiers in immunology · 2025Review
- Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- IFI27 enhances bladder cancer immunotherapy response by modulating regulatory T cell enrichment.Journal of Cancer · 2024Article
- A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues.Frontiers in immunology · 2024Article
- Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updates.Bladder cancer (Amsterdam, Netherlands)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
purposeThe activity and safety of neoadjuvant nivolumab plus gemcitabine/cisplatin (N+GC) were tested in patients with muscle-invasive bladder urothelial carcinoma (MIBC). Materials and Methods: In a prospective phase II trial, patients with cT2-T4a N0 MIBC who were eligible for cisplatin and medically appropriate to undergo radical cystectomy (RC) were enrolled. Treatment with nivolumab 3 mg/kg on days 1 and 15 plus GC (cisplatin 70 mg/m2 on day 1, and gemcitabine 1,000 mg/m2 on days 1, 8, and 15) was repeated every 28 days up to 3 or 4 cycles, depending on the surgery schedules. The primary endpoint was pathologic complete response (pCR, ypT0). Secondary endpoints included pathologic downstaging (≤ ypT1), disease-free survival (DFS), and safety.
resultsBetween September 2019 and October 2020, 51 patients were enrolled. Neoadjuvant N+GC was well tolerated. Among 49 patients who completed neoadjuvant N+GC, clinical complete response (cCR) was achieved in 59% of intent-to-treat (ITT) population. RC was performed in 34 (69%) patients. pCR was achieved in 24% (12/49) of ITT population and 35% (12/34) of RC patients. Median DFS was not reached. Over a median follow-up of 24 months, 12 patients experienced disease recurrence and were treated with palliative therapy or surgery. Although 12 patients declined surgery and were treated with concurrent chemoradiotherapy, DFS was longer in patients with cCR after neoadjuvant therapy than those without. Preoperative programmed death-ligand 1 (PD-L1) did not correlate with pCR or pathologic downstaging rates.
conclusionNeoadjuvant N+GC was feasible and provided meaningful pathologic responses in patients with MIBC, regardless of baseline PD-L1 expression (ONO-4538-X41; CRIS.nih.go.kr, KCT0003804).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.